Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of sugammadex on early postoperative recovery in kidney transplant recipients
ChiCTR2300072693Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Jul 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in end-stage kidney disease (ESKD) (4 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Time of onset of muscle relaxation antagonist, Recovery time for spontaneous breathing and 7 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2300072693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072693.